TY - JOUR
T1 - Alginate@TiO2 hybrid microcapsules with high in vivo biocompatibility and stability for cell therapy
AU - Leroux, Grégory
AU - Neumann, Myriam
AU - Meunier, Christophe F.
AU - Voisin, Virginie
AU - Habsch, Isabelle
AU - Caron, Nathalie
AU - Michiels, Carine
AU - Wang, Li
AU - Su, Bao Lian
N1 - Funding Information:
This work was supported by Program for Changjiang Scholars and Innovative Research Team in University (IRT_15R52) and “ Algae Factory ” ( 1610187 ) European H2020 program financed by FEDER and Wallonia Region of Belgium . G. Leroux thanks the University of Namur for his assistant position to realize his PhD research. We are grateful to Laetitia Giordano and Vanessa Colombaro of URPhyM for their help and advices on animal experiments. We thank Prof. Yves Poumay, Daniel Van Vlaender and Valérie De Glas of LabCeTi for their support in histological techniques and examination. The present work is in accordance with the rules of the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the project was approved by the Committee on the Ethics of Animal Experiments of the University of Namur.
Funding Information:
This work was supported by Program for Changjiang Scholars and Innovative Research Team in University (IRT_15R52) and ?Algae Factory? (1610187) European H2020 program financed by FEDER and Wallonia Region of Belgium. G. Leroux thanks the University of Namur for his assistant position to realize his PhD research. We are grateful to Laetitia Giordano and Vanessa Colombaro of URPhyM for their help and advices on animal experiments. We thank Prof. Yves Poumay, Daniel Van Vlaender and Val?rie De Glas of LabCeTi for their support in histological techniques and examination. The present work is in accordance with the rules of the National Institutes of Health Guide for the Care and Use of Laboratory Animals and the project was approved by the Committee on the Ethics of Animal Experiments of the University of Namur.
Publisher Copyright:
© 2021 Elsevier B.V.
PY - 2021/7
Y1 - 2021/7
N2 - Designing new materials to encapsulate living therapeutic cells for the treatment of the diseases caused by protein or hormone deficiencies is a great challenge. The desired materials need to be biocompatible towards both entrapped cells and host organisms, have long-term in vivo stability after implantation, allow the diffusion of nutrients and metabolites, and ensure perfect immune-isolation. The current work investigates the in vivo biocompatibility and stability of alginate@TiO2 hybrid microcapsules and the immune-isolation of entrapped HepG2 cells, to assess their potential for cell therapy. A comparison was made with alginate-silica hybrid microcapsules (ASA). These two hybrid microcapsules are implanted subcutaneously in female Wistar rats. The inflammatory responses of the rats are monitored by the histological examination of the implants and the surrounding tissues, to indicate their in vivo biocompatibility towards the hosts. The in vivo stability of the microcapsules is evaluated by the recovery rate of the intact microcapsules after implantation. The immune-isolation of the entrapped cells is assessed by their morphology, membrane integrity and intracellular enzymatic activity. The results show high viability of the entrapped cells and insignificant inflammation of the hosts, suggesting the excellent biocompatibility of alginate@TiO2 and ASA microcapsules towards both host organisms and entrapped cells. Compared to the ASA microcapsules, more intact alginate@TiO2 hybrid microcapsules are recovered 2-day and 2-month post-implantation and more cells remain alive, proving their better in vivo biocompability, stability, and immune-isolation. The present study demonstrates that the alginate@TiO2 hybrid microcapsule is a highly promising implantation material for cell therapy.
AB - Designing new materials to encapsulate living therapeutic cells for the treatment of the diseases caused by protein or hormone deficiencies is a great challenge. The desired materials need to be biocompatible towards both entrapped cells and host organisms, have long-term in vivo stability after implantation, allow the diffusion of nutrients and metabolites, and ensure perfect immune-isolation. The current work investigates the in vivo biocompatibility and stability of alginate@TiO2 hybrid microcapsules and the immune-isolation of entrapped HepG2 cells, to assess their potential for cell therapy. A comparison was made with alginate-silica hybrid microcapsules (ASA). These two hybrid microcapsules are implanted subcutaneously in female Wistar rats. The inflammatory responses of the rats are monitored by the histological examination of the implants and the surrounding tissues, to indicate their in vivo biocompatibility towards the hosts. The in vivo stability of the microcapsules is evaluated by the recovery rate of the intact microcapsules after implantation. The immune-isolation of the entrapped cells is assessed by their morphology, membrane integrity and intracellular enzymatic activity. The results show high viability of the entrapped cells and insignificant inflammation of the hosts, suggesting the excellent biocompatibility of alginate@TiO2 and ASA microcapsules towards both host organisms and entrapped cells. Compared to the ASA microcapsules, more intact alginate@TiO2 hybrid microcapsules are recovered 2-day and 2-month post-implantation and more cells remain alive, proving their better in vivo biocompability, stability, and immune-isolation. The present study demonstrates that the alginate@TiO2 hybrid microcapsule is a highly promising implantation material for cell therapy.
KW - Cell encapsulation
KW - Hybrid hydrogels
KW - Immune isolation
KW - In vivo biocompatibility
KW - In vivo stability
UR - http://www.scopus.com/inward/record.url?scp=85104442498&partnerID=8YFLogxK
U2 - 10.1016/j.colsurfb.2021.111770
DO - 10.1016/j.colsurfb.2021.111770
M3 - Article
AN - SCOPUS:85104442498
SN - 0927-7765
VL - 203
JO - Colloids and Surfaces B: Biointerfaces
JF - Colloids and Surfaces B: Biointerfaces
M1 - 111770
ER -